» Articles » PMID: 25788530

Recipient Myd88 Deficiency Promotes Spontaneous Resolution of Kidney Allograft Rejection

Overview
Specialty Nephrology
Date 2015 Mar 20
PMID 25788530
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

The myeloid differentiation protein 88 (MyD88) adapter protein is an important mediator of kidney allograft rejection, yet the precise role of MyD88 signaling in directing the host immune response toward the development of kidney allograft rejection remains unclear. Using a stringent mouse model of allogeneic kidney transplantation, we demonstrated that acute allograft rejection occurred equally in MyD88-sufficient (wild-type [WT]) and MyD88(-/-) recipients. However, MyD88 deficiency resulted in spontaneous diminution of graft infiltrating effector cells, including CD11b(-)Gr-1(+) cells and activated CD8 T cells, as well as subsequent restoration of near-normal renal graft function, leading to long-term kidney allograft acceptance. Compared with T cells from WT recipients, T cells from MyD88(-/-) recipients failed to mount a robust recall response upon donor antigen restimulation in mixed lymphocyte cultures ex vivo. Notably, exogenous IL-6 restored the proliferation rate of T cells, particularly CD8 T cells, from MyD88(-/-) recipients to the proliferation rate of cells from WT recipients. Furthermore, MyD88(-/-) T cells exhibited diminished expression of chemokine receptors, specifically CCR4 and CXCR3, and the impaired ability to accumulate in the kidney allografts despite an otherwise MyD88-sufficient environment. These results provide a mechanism linking the lack of intrinsic MyD88 signaling in T cells to the effective control of the rejection response that results in spontaneous resolution of acute rejection and long-term graft protection.

Citing Articles

Interleukin-2/anti-interleukin-2 immune complex attenuates cold ischemia-reperfusion injury after kidney transplantation by increasing renal regulatory T cells.

Jang J, Kim H, Yan J, Kang T, Lee W, Kim B Clin Transl Med. 2024; 14(3):e1631.

PMID: 38504554 PMC: 10951489. DOI: 10.1002/ctm2.1631.


Antibody-suppressor CXCR5 CD8 T cellular therapy ameliorates antibody-mediated rejection following kidney transplant in CCR5 KO mice.

Zimmerer J, Han J, Peterson C, Zeng Q, Ringwald B, Cassol C Am J Transplant. 2022; 22(6):1550-1563.

PMID: 35114045 PMC: 9177711. DOI: 10.1111/ajt.16988.


Prevention of vascular-allograft rejection by protecting the endothelial glycocalyx with immunosuppressive polymers.

Siren E, Luo H, Tam F, Montgomery A, Enns W, Moon H Nat Biomed Eng. 2021; 5(10):1202-1216.

PMID: 34373602 DOI: 10.1038/s41551-021-00777-y.


Untangling Local Pro-Inflammatory, Reparative, and Regulatory Damage-Associated Molecular-Patterns (DAMPs) Pathways to Improve Transplant Outcomes.

Dwyer G, Turnquist H Front Immunol. 2021; 12:611910.

PMID: 33708206 PMC: 7940545. DOI: 10.3389/fimmu.2021.611910.


Kidney-intrinsic factors determine the severity of ischemia/reperfusion injury in a mouse model of delayed graft function.

Qiu L, Lai X, Wang J, Yeap X, Han S, Zheng F Kidney Int. 2020; 98(6):1489-1501.

PMID: 32822703 PMC: 7814505. DOI: 10.1016/j.kint.2020.07.033.


References
1.
Nakajima C, Mukai T, Yamaguchi N, Morimoto Y, Park W, Iwasaki M . Induction of the chemokine receptor CXCR3 on TCR-stimulated T cells: dependence on the release from persistent TCR-triggering and requirement for IFN-gamma stimulation. Eur J Immunol. 2002; 32(6):1792-801. DOI: 10.1002/1521-4141(200206)32:6<1792::AID-IMMU1792>3.0.CO;2-0. View

2.
Rose-John S, Neurath M . IL-6 trans-signaling: the heat is on. Immunity. 2004; 20(1):2-4. DOI: 10.1016/s1074-7613(04)00003-2. View

3.
Quigley M, Martinez J, Huang X, Yang Y . A critical role for direct TLR2-MyD88 signaling in CD8 T-cell clonal expansion and memory formation following vaccinia viral infection. Blood. 2008; 113(10):2256-64. PMC: 2652371. DOI: 10.1182/blood-2008-03-148809. View

4.
Ohsugi Y . Recent advances in immunopathophysiology of interleukin-6: an innovative therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseases. Biol Pharm Bull. 2007; 30(11):2001-6. DOI: 10.1248/bpb.30.2001. View

5.
Bosschaerts T, Guilliams M, Stijlemans B, Morias Y, Engel D, Tacke F . Tip-DC development during parasitic infection is regulated by IL-10 and requires CCL2/CCR2, IFN-gamma and MyD88 signaling. PLoS Pathog. 2010; 6(8):e1001045. PMC: 2920868. DOI: 10.1371/journal.ppat.1001045. View